+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO)



99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO)



Clinical Nuclear Medicine 38(8): 664-667



Tumors that cause osteomalacia are generally benign fibroblast growth factor-23 producing mesenchymal tumors which can be detected by octreoscan. A 45-year-old man underwent (99m)Tc-HYNIC-TOC scan to detect a possible culprit causing osteomalacia. The images showed abnormal activity in the left humerus and in the right foot. The lesion of the right foot was confirmed pathologically as phosphaturic mesenchymal tumor. After surgical removal of the tumor in the right foot, the patient's symptoms were promptly improved. However, the improvement was transient due to the unresected tumor in the left humerus.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051053661

Download citation: RISBibTeXText

PMID: 23797229

DOI: 10.1097/rlu.0b013e3182996293


Related references

Osteomalacia-inducing renal clear cell carcinoma uncovered by 99mTc-Hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC) scintigraphy. Clinical Nuclear Medicine 38(11): 922-924, 2013

99mTc-N4-[Tyr3]Octreotate Versus 99mTc-EDDA/HYNIC-[Tyr3]Octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer BioTherapy and Radiopharmaceuticals 19(1): 73-79, 2004

Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor. Minerva Endocrinologica 41(1): 10-18, 2016

Specificity and sensitivity of ⁹⁹mTc-EDDA/HYNIC-Tyr³-octreotide (⁹⁹mTc-TOC) for imaging neuroendocrine tumors. Nuclear Medicine Communications 33(1): 69-79, 2012

Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors. Journal of Nuclear Medicine 52(9): 1474-1481, 2011

Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys. Nuclear Medicine and Biology 31(2): 231-239, 2004

A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Nuclear Medicine and Biology 42(12): 911-916, 2015

Preparation via coligand exchange and characterization of (99mTc-EDDA-HYNIC-D-Phe1,Tyr3)Octreotide (99mTc-EDDA/HYNIC-TOC). Journal of Labelled Compounds and Radiopharmaceuticals 46(4): 307-318, 2003

Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy. Clinical Nuclear Medicine 32(3): 182-185, 2007

Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers. Clinical Nuclear Medicine 38(5): 321-325, 2013

Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. European Journal of Radiology 82(11): 2028-2034, 2013

99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. Journal of Nuclear Medicine 41(6): 1114-1119, 2000

99mTc-EDDA-HYNIC-Tyr3-octreotide for detection of somatostatin receptor positive tumors and first experience in patients. Journal of Nuclear Medicine 41(5 Suppl ): 149P-150P, 2000

99mTc-N4- octreotate versus 99mTc-EDDA/HYNIC- octreotide An intrapatient comparison of two novel technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biotherapy & Radiopharmaceuticals 19(1): 73-79, 2004

Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. Journal of Pharmaceutical Sciences 93(10): 2497-2506, 2004